Evidence map›Paper›PMID 39708205›Full record

ArticleJournal of neurology2024

Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.

Mihaela Nicolescu, Vivien Häußler, Friedemann Paul, Frederike Cosima Oertel, Patrick Schindler, Judith Bellmann Strobl, Markus Krumbholz, Martin W Hümmert, Franziska Bütow, Daria Tkachenko and 38 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors.

Mihaela NicolescuAPHM, Hôpital de la Timone, CEMEREM, Marseille, France. m3nicolescu9@gmail.com.ORCID http://orcid.org/0009-0007-3596-9515
Vivien HäußlerDepartment of Neurology and Institute of Neuroimmunology and MS (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Friedemann PaulNeuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Frederike Cosima OertelNeuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Patrick SchindlerNeuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Judith Bellmann StroblNeuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Markus KrumbholzDepartment of Neurology and Pain Treatment, Multiple Sclerosis Center, Center for Translational Medicine, Immanuel Klinik Rüdersdorf, University Hospital of the Brandenburg Medical School Theodor Fontane, Rüdersdorf Bei Berlin, Germany.
Martin W HümmertDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Franziska BütowDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Daria TkachenkoDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Corinna TrebstDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Charlotte SchubertDepartment of Neurology and Institute of Neuroimmunology and MS (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ilya AyzenbergDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Carolin SchwakeDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Thivya PakeerathanDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Katinka FischerDepartment of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Orhan AktasDepartment of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Marius RingelsteinDepartment of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Markus KraemerDepartment of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Clemens WarnkeDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-3510-9255
Matthias GrotheDepartment of Neurology, University of Greifswald, Greifswald, Germany.
Matthias KasteDepartment of Neurology, Nordwest Hospital Sanderbusch, Sande, Germany.
Klemens AngstwurmDepartment of Neurology, University of Regensburg, Regensburg, Germany.
Peter KernDepartment of Neurology, Asklepios Expert Clinic Teupitz, Teupitz, Germany.
Ingo KleiterMarianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen Für Multiple Sklerose Kranke, Berg, Germany.
Paulus RommerDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Alexander WinkelmannDepartment of Neurology, Rostock University Medical Center, Rostock, Germany.
Annette WalterDepartment of Neurology, Herford Hospital, Herford, Germany.
Martin S WeberInstitute of Neuropathology, Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Jonathan WickelSection of Translational Neuroimmunology, Department of Neurology, Jena University Hospital, Jena, Germany.
Katrin GiglhuberDepartment of Neurology, School of Medicine and Health, Technical University Munich, TUM Universitätsklinikum, Munich, Germany.
Florian Then BerghDepartment of Neurology, University of Leipzig, Leipzig, Germany.
Makbule SenelDepartment of Neurology, University of Ulm, Ulm, Germany.
Hayrettin TumaniDepartment of Neurology, University of Ulm, Ulm, Germany.
Ioannis VardakasDepartment of Neurology, University of Ulm, Ulm, Germany.
Eva DawinDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
Lisa RevieDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
Luisa KlotzDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
Mirjam Korporal-KuhnkeMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Sven JariusMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Brigitte WildemannMolecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Jonathan A GernertInstitute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.
Tania KümpfelInstitute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.
Daniel EngelsInstitute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-9877-6987
Joachim HavlaInstitute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-4386-1340
Natacha Stolowy *APHM, Hôpital de la Timone, CEMEREM, Marseille, France.
Jan-Patrick Stellmann *APHM, Hôpital de la Timone, CEMEREM, Marseille, France.
Neuromyelitis Optica Study Group (NEMOS)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn this multicentric study, we were interested in the vision-related quality of life and its association with visual impairment in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in comparison to multiple sclerosis (MS) and healthy controls.

methodsWe analysed extracted data from the German NEMOS registry including National Eye Institute Visual Function Questionnaire (NEI-VFQ) scores, high and low contrast visual acuity (HCVA, LCVA), visually evoked potentials (VEP) and the scores for the expanded disability status scale (EDSS) and other neurological tests which assessed their disease-related impairment. The mean follow-up time of our patients was 1.2 years. We used adjusted linear mixed effect models to analyse NEI-VFQ differences and interactions with visual acuity among NMOSD, MOGAD, a matched MS cohort and healthy controls.

resultsDespite a younger age in the MOGAD cohort (39 y.o.), vision and socioemotional-related quality of life reduction was similar over all patient subgroups in comparison to healthy controls. The most impacted life quality dimension was general health, followed by general vision, driving and role difficulties. Decline in some of the NEI-VFQ subscales scores is mostly predicted by age. The HCVA was the best predictor for most of the subscales of the NEI-VFQ. DISCUSSION: Despite important age differences, NMOSD, MOGAD and MS seem to share a rather similar perception on their vision and quality of life impairment, which is overall poorer than that of healthy controls.

Indexed as

Evoked Potentials, VisualNeuromyelitis OpticaQuality of LifeVisual AcuityAdultAgedAgingDemyelinating Autoimmune Diseases, CNSFemaleGermanyHumansMaleMiddle AgedMultiple SclerosisMyelin-Oligodendrocyte GlycoproteinRegistriesMyelin-Oligodendrocyte GlycoproteinLife qualityNEI-VFQNeuroinflammatory diseasesNMOSDVisionVisual tests

Identifiers

PMID39708205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.